Logo

Bionano Genomics: Alka Chaubey

Aug 18, 2020

Bionano Genomics has appointed Alka Chaubey as its first chief medical officer, effective Aug. 31, 2020.

Chaubey, a cytogeneticist, will be responsible for driving adoption of the firm's Saphyr optical genome mapping platform for use in clinical applications.

She brings nearly 20 years of scientific and clinical experience and has developed and validated clinical tests, including US Food and Drug Administration-cleared whole-genome cyotgenetic tests. She comes to Bionano from PerkinElmer, where she is head of the cytogenomics. She is also an adjunct assistant professor of pathology at the Medical College of Georgia at Augusta University and is scientific director of the Georgia Esoteric and Molecular Laboratory and the Augusta University Medical Center cytogenetics laboratory. Before coming to PerkinElmer, she directed the Greenwood Genetic Center's cytogenomics laboratory.

Chaubey holds a doctorate in biochemistry and molecular biology from India's Guru Nanak Dev University.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.